PubMed Health⌕ Search

PubMed · 11764341

A low stiffness composite biologically fixed prosthesis.

Abstract

The current authors addressed the question whether stress-induced adaptive bone remodeling of the proximal femur is a necessary consequence after total hip reconstruction with extensively biologically-fixed femoral components. A novel total hip femoral component was designed to simultaneously achieve stable skeletal fixation, structural durability, and reduced femoral stress shielding. This implant allowed for proximal and distal canal filling, yet was significantly less rigid than all-metallic femoral stems crafted of either cobalt chromium or titanium alloy. A cohort of 366 patients (386 hips) treated at 21 institutions worldwide now have been followed up a mean of 2.4 years postoperatively (range, 3 months-6 years). Two hundred sixty-eight patients have 2 years minimum followup. To date, no femoral implants have failed to achieve bone ingrowth and none have required revision. The implants appear radiographically well-fixed with no progressive radiolucencies or osteolysis. Radiostereometric analysis studies on one subset of patients showed stable initial fixation and minimal stem micromotion. Dual energy xray absorptiometry analysis on another subset of patients revealed excellent periprosthetic bone mineral density retention. Compared with more rigid metal implants, this design shows reduced proximal femoral bone loss secondary to stress-mediated bone resorption.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A H Glassman, R D Crowninshield, R Schenck, P Herberts. 2001. A low stiffness composite biologically fixed prosthesis.. https://doi.org/10.1097/00003086-200112000-00015

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A repeated measures concordance correlation coefficient.

The concordance correlation coefficient is commonly used to assess agreement between two raters or two methods of measuring a response when the data are measured on a continuous scale. However, the situation may arise in which repeated measurements are taken for each rater or method, e.g. longitudinal studies in clinical trials or bioassay data with subsamples. This paper proposes a coefficient for measuring agreement between two raters or two methods of measuring a response in the presence of repeated measurements. We illustrate the methodology with examples comparing (1) 1-hr versus 2-hr blood draws for measuring cortisol in an asthma clinical trial and (2) two measurements of percentage body fat, from skinfold calipers and dual energy X-ray absorptiometry.

Absorptiometry, Photon↗

Crystallization and preliminary X-ray analysis of a domain in the Runx2 transcription factor that interacts with the 1alpha,25 dihydroxy vitamin D3 receptor.

The Runx2 transcription factor is a key regulator of osteoblast differentiation. In response to 1alpha,25 dihydroxy vitamin D3, Runx2 may interact with the 1alpha,25 dihydroxy vitamin D3 receptor (VDR) in the promoter of target genes, producing a synergic activation of their transcription. Previous studies have suggested that the motifs responsible for the VDR-Runx2 interaction are contained within the 230-361 domain of Runx2. In this work, we confirmed by GST-pull down that Runx2(I(209-361)) is sufficient to interact with the VDR. To obtain structural information, GST-Runx2(I(209-361)) protein was overexpressed in Escherichia coli, purified and crystallized using the hanging-drop vapor-diffusion method and polyethyleneglycol as a precipitant. The crystals were found to diffract to a maximum resolution of 2.7 A and a complete data set to a 3.3 A resolution was collected and analyzed. The crystals belong to the tetragonal system, with a space group P4 and unit-cell parameters of a = b = 90.8, and c = 57.2 A. The presence of a monomer of the recombinant GST-Runx2(I(209-361)) in the asymmetric unit gives a V(M) of 2.7 A(3) Da(-1) and a solvent content of 54.8%.

Absorptiometry, Photon↗

Quantifying the treatment effect explained by markers in the presence of measurement error.

Surrogate markers or intermediate markers are important in identifying subjects with high risk of a serious disease or for monitoring disease progression of a subject on treatment. Quantifying the proportion of treatment effect (PTE) explained by markers has been studied extensively. Due to reasons such as biological variation, limited machine precision, etc. markers are generally measured with error. The estimated PTE ignoring the measurement error could be biased, which may lead to incorrect conclusions. In this article, we adjust for the measurement error using regression calibration to construct a less biased estimator of excess relative odds, a quantity to measure the treatment effect explained by markers. The method is applied to data from a clinical study in osteoporosis.

Absorptiometry, Photon↗